JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

PSMA Radiotheranostics in Prostate Cancer: Principles, Practice, and Future Prospects

  • 0From the Department of Diagnostic Radiology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, L340, Portland, OR 97239 (L.K.S., D.B., N.M.); Bristol Haematology and Oncology Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom (A.C.); and Department of Radiology, Charing Cross Hospital, Imperial College Health Care NHS Trust, London, United Kingdom (T.D.B., M.N., A.E.).
Radiographics : a Review Publication of the Radiological Society of North America, Inc +

|

November 21, 2024

|

November 21, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Lutetium 177 (<sup>177</sup>Lu)-PSMA radioligand therapy offers a promising new treatment for metastatic castration-resistant prostate cancer. This approach, utilizing prostate-specific membrane antigen (PSMA) targeting, improves survival and quality of life.

Area Of Science

  • Nuclear Medicine
  • Oncology
  • Radiopharmaceutical Therapy

Background

  • Metastatic castration-resistant prostate cancer (mCRPC) poses significant treatment challenges.
  • Prostate-specific membrane antigen (PSMA) is a key target for advanced prostate cancer therapies.
  • <sup>177</sup>Lu-PSMA radioligand therapy represents an emerging treatment modality for mCRPC.

Purpose Of The Study

  • To review the current landscape of PSMA-based radioligand therapy for mCRPC.
  • To discuss patient selection, treatment administration, and response assessment.
  • To highlight future directions in PSMA-targeted prostate cancer treatment.

Main Methods

  • Review of current practices in <sup>177</sup>Lu-PSMA radioligand therapy administration and dosing.
  • Focus on eligibility criteria and the role of PSMA PET imaging for patient selection and monitoring.
  • Discussion of response assessment criteria and post-therapy imaging.

Main Results

  • <sup>177</sup>Lu-PSMA-617 approval, based on the VISION trial, demonstrated improved overall survival and quality of life in mCRPC patients.
  • PSMA expression assessment via PSMA PET is critical for treatment eligibility.
  • Current practices, side effects, and the value of post-therapy imaging are discussed.

Conclusions

  • <sup>177</sup>Lu-PSMA radioligand therapy is a significant advancement in mCRPC treatment.
  • Further validation of response assessment criteria using PSMA PET is needed.
  • Ongoing trials explore new PSMA agents, earlier treatment stages, and combination therapies for prostate cancer.

Related Concept Videos

Positron Emission Tomography 01:29

4.0K

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

Imaging Studies II: Positron Emission Tomography and Scintigraphy 01:25

86

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Radioactive Tracer: PET involves using biologically active molecules labeled with radioactive isotopes, known as tracers or radiotracers. The...

Targeted Cancer Therapies 02:57

7.5K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Radiological Investigation III: Pulmonary Angiogram and PET Scan 01:13

86

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...